IPO Premiums
IPO calendar
RRListed

Rubicon Research Limited

Bookbuilding IPO · NSE, BSE

Price band
₹461 - ₹485
Lot size
30 shares
Issue amount
₹1,377.5 cr
Total subscription
109.33×
Current price₹1,486.7
Listing price ₹620.1
Watch live price ↗
Opens
9 Oct 2025
Closes
13 Oct 2025
Allotment
14 Oct 2025
Listing
16 Oct 2025

Offer at a glance

Issue overview

Issue size
2,84,02,040 shares
Face value
₹1 Per Share
Minimum investment
₹13,830
Fresh issue
₹500 cr
Offer for sale
₹877.5 cr
Registrar
Link Intime India Private Ltd (MUFG)
Listing exchange
NSE, BSE
Maximum investment
₹14,550
Issue type
Bookbuilding IPO
Shares before issue
15,44,37,251
Shares after issue
16,47,46,529

Lot sizes

CategoryLotsSharesAmount
Retail130₹14,550
sHNI14420₹2,03,700
bHNI692,070₹10,03,950

Share reservation

Anchor44.94%
QIB29.95%
HNI14.98%
RETAIL9.99%
Employee0.14%

Subscription & GMP

Subscription by category

Total subscribed109.33×

Reported 13 Oct 2025

QIB137.09×
NIB102.71×
RETAIL37.33×
EMPLOYEES17.69×
HNIs(10L+)117.77×
HNIs(2-10L)72.57×

GMP history

0601203 Oct: ₹04 Oct: ₹345 Oct: ₹366 Oct: ₹647 Oct: ₹648 Oct: ₹789 Oct: ₹8010 Oct: ₹8911 Oct: ₹8812 Oct: ₹8213 Oct: ₹9414 Oct: ₹12015 Oct: ₹1206 Nov: ₹12020 May: ₹120
3 Oct₹12020 May

Day-wise demand

9 Oct0.55×
10 Oct2.51×
13 Oct109.33×

Application-wise demand

CategoryReserved applicationsApplied applications
RETAIL94,54027,93,192
EMPLOYEES015,968
HNIs(10L +)6,7531,55,448
HNIs (2-10L)3,3762,34,124

Subscription demand

Amounts in ₹ crore. HNI subcategories are included in the NII total.

CategoryOfferedDemand
QIBs412.5856,559.14
FIIs016,406.1
FIs024,566.34
Mutual Funds02,842.57
Others012,744.13
RETAIL137.565,134.48
HNIs 2+68.784,991.47
HNIs 10+137.5616,200.08
EMPLOYEES1.9434.35

Financial performance

Company financials

In Crores · Reported periods may include interim results.

Revenue & profit In Crores
-50005001,0001,500Mar-23 · Revenue: 419Mar-23 · Profit after tax: -16.89Mar-23Mar-24 · Revenue: 872.39Mar-24 · Profit after tax: 91.01Mar-24Mar-25 · Revenue: 1,296.22Mar-25 · Profit after tax: 134.36Mar-25Jun-25 · Revenue: 356.95Jun-25 · Profit after tax: 43.3Jun-25
RevenueProfit after tax

Key performance indicators

MetricMar-25Mar-24Mar-23
EPS8.825.98-1.11
ROE29.0227.11-5.71
ROCE26.4518.621.35
RONW000
PRE IPO(PE)000
POST IPO(PE)000

Values and labels as reported in the issue data.

Peer comparison

CompanyP/E(X)CMP* (₹)Face value (₹)NAV/Share (₹)RONW(%)EPS (Basic) (₹)
Aurobindo Pharma Limited18.121,083.851.00560.2211.1559.81
Sun Pharmaceutical Industries Limited34.981,594.951.00300.9916.1645.60
Rubicon Research LimitedNANA1.0035.5329.028.82
Zydus Lifesciences Limited21.83981.701.00238.0521.3444.97
Strides Pharma Science Limited18.72824.7510.00238.0521.3444.97
Dr. Reddy’s Laboratories Limited18.051,223.701.00402.7818.5367.89
Alembic Pharmaceuticals Limited30.33900.22.00264.0911.6329.68
Lupin Limited26.641,910.152.00377.1821.0071.95

Company information

Company profile

Rubicon Research Limited, incorporated in 1999, is a pharmaceutical company focused on developing, manufacturing, and commercializing differentiated formulations. As of June 30, 2025, it has 72 US FDA-approved ANDA and NDA products, with 66 commercialized in a US generic market worth USD 2,455.7 million, contributing USD 195 million in Fiscal 2024. The company has 17 products awaiting US FDA approval and 63 in development, marketing over 350 SKUs to 96 customers, including major wholesalers, pharmacy chains, GPOs, and managed care organizations. Globally, Rubicon has registered or filed 48 products across Australia, the UK, Singapore, Saudi Arabia, and the UAE, planning commercial launch upon approval, and offers contract manufacturing in India, Australia, and New Zealand. Its operations include three manufacturing facilities in India and two US FDA-inspected R&D centers in India and Canada.

Strengths

  • Robust Product Portfolio: Data-driven selection creates a balanced mix of new and specialty products, helping manage pricing pressures.
  • Strong R&D Capabilities: Continuous investment in research enables development of complex, high-revenue products.
  • Proven Compliance & Quality Manufacturing: Maintains regulatory standards with cost-effective production and strong quality systems.

Risk factors

  • Regulatory & Compliance Risks: Strict manufacturing rules may cause recalls, failed inspections, or plant closures, affecting sales and new launches.
  • Financial Performance Risks: Past losses mean profitability depends on growing revenue and managing costs.
  • High Capital Requirements: Large working capital and investments are needed; funding issues could disrupt operations.

Promoters

Pratibha Pilgaonkar

Sudhir Dhirendra Pilgaonkar

Parag Suganchand Sancheti

Surabhi Parag Sancheti

Sumant Sudhir Pilgaonkar

Registrar & documents

Lead manager

Axis Capital Limited, IIFL Capital Services Limited, Jm Financial Limited, SBI Capital Markets Limited

Registered office

MedOne House, B-75, Road No. 33, Wagle Estate, Thane, Maharashtra, 400604

022 61414000

[email protected]Company website ↗

Frequently Asked Questions

What is Rubicon Research IPO GMP today?

As of today, Rubicon Research IPO Grey Market Premium (GMP) is reported at +₹120 per share. Based on the upper price band of ₹485, the estimated listing price is ₹605 (+24.7% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.

What is the lot size and minimum investment for Rubicon Research IPO?

The minimum bid lot size for Rubicon Research IPO is 30 shares. At the cut-off price of ₹485 per share, retail investors need a minimum application amount of ₹14,550 per lot. Retail applicants can apply for a maximum of 13 lots (up to ₹2,00,000).

When will Rubicon Research IPO allotment status be announced?

The allotment status for Rubicon Research IPO is scheduled to be finalized on 14 Oct 2025. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Link Intime India Private Ltd (MUFG)'s official portal or via BSE/NSE allotment portals.

How can I check Rubicon Research IPO allotment status online by PAN?

To check Rubicon Research IPO allotment status: 1) Visit the registrar portal (Link Intime India Private Ltd (MUFG)) or the BSE IPO allotment page. 2) Select 'Rubicon Research Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.

Explore More IPO Analysis & Live Tools

Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.

Regulatory Disclaimer: Grey Market Premium (GMP) is an unofficial, unregulated indicator of market sentiment and does not represent a stock exchange transaction, guarantee, or investment advice. IPO Premiums is an informational and research portal and is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before applying for any IPO.